PAT-DARUNAVIR TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DARUNAVIR (DARUNAVIR ETHANOLATE)

Pieejams no:

PATRIOT A DIVISION OF JANSSEN INC

ATĶ kods:

J05AE10

SNN (starptautisko nepatentēto nosaukumu):

DARUNAVIR

Deva:

400MG

Zāļu forma:

TABLET

Kompozīcija:

DARUNAVIR (DARUNAVIR ETHANOLATE) 400MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

60

Receptes veids:

Prescription

Ārstniecības joma:

HIV PROTEASE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0151656002; AHFS:

Autorizācija statuss:

CANCELLED PRE MARKET

Autorizācija datums:

2020-03-12

Produkta apraksts

_ _
_Page 1 of 78 _
PRODUCT
MONOGRAPH
PR
PAT-DARUNAVIR
darunavir tablets 75 mg, 150 mg, 400 mg, 600 mg, 800 mg
(as darunavir ethanolate)
Human Immunodeficiency Virus (HIV) Protease Inhibitor
Patriot, a division of Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Date of Preparation:
November 30, 2012
www.patriot-canada.ca
Submission Control No: 159996
© JANSSEN Inc. 2012
All trademarks used under license.
Draft Date: Oct 26, 2012
_ _
_Page 2 of 78 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
20
DOSAGE AND ADMINISTRATION
.....................................................................................
32
OVERDOSAGE
.......................................................................................................................
35
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 35
STORAGE AND STABILITY
.................................................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 38
PART II: SCIENTIFIC INFORMATION
..............................................................................
40
PHARMACEUTICAL INFORMATION
.............................